3Helix Inc. is a biotechnology company headquartered in Salt Lake City, Utah, founded in 2015. The company specializes in Collagen Hybridizing Peptides (CHPs), proprietary short peptides that selectively target and bind to damaged or denatured collagen by exploiting differences in 3D structure from healthy collagen.
3Helix develops and markets labeled CHP conjugates—such as biotin, 5-FAM, Cy3, and sulfo-Cy7.5 variants—for life science research tools, enabling applications in diagnostics, histopathology, pathology, biomechanics, cell biology, and regenerative medicine to study collagen remodeling in diseases like fibrosis, inflammation, aging, and wound healing.
In therapeutics, the company advances bioACTIVE CHPs to modulate collagen-driven processes for potential treatments. For the cosmetics sector, 3Helix partnered with BASF in 2023 through an equity investment and licensing deal, granting BASF exclusive rights to commercialize CHP solutions in personal care, including anti-aging products like NeoHelix Regenerate.
